Health Care Network

New on HCN: the midterms and what they could mean for healthcare, from ACA subsidies to Medicaid to peptides.
Plus Tanishq Abraham on Sophont's healthcare world model and Andrew Brackin on Vera Health.
@brackin
@iScienceLuvr

x.com/i/broadcasts/2…

The FDA's pooled look at 126 trials found 15 probable cases of this eye condition among 134,253 patients. 10 were on a GLP-1 and 5 were on placebo. That's rare, but it was enough to put a warning on every drug in the class.

The tricky part is that the FDA's list of NAION risk factors includes diabetes, high blood pressure, and sleep apnea, which are the same conditions a lot of people take these drugs for. That overlap makes the drug's own share of the risk hard to pin down.

Medicaid expansion could be the slow road to Medicare for All.

@cedrickojo and @operationdanish on what newly elected governors might do and how the ACA marketplace could change.

Congrats to @julesyoo on Oura's $625 million deal for Counsel Health. She chatted with us on Ep. 9 of HCN, and her write-up here on why Counsel and Oura fit together is worth the read.

"If you're optimizing your Al system for these evals, you may actually be making your product worse for the end user, for the physician."

@brackin of @GradientVC on why the way we score medical Al is broken.